Clinical Trials at NEXT Oncology
As of September 2026, 56 paid clinical trials are recruiting at NEXT Oncology, located at 22151 BULVERDE RD STE 106, SAN ANTONIO, TX 78259-1850, phone (281) 783-8162 in San Antonio, Texas. Active studies at this site cover conditions such as Advanced Solid Tumor, Advanced Solid Tumors and Obesity. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in San Antonio
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors
59 clinical trials at NEXT Oncology
·Clear filters·A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
A Study of ASP3082 in Adults With Advanced Solid Tumors
A Study of TAK-505 in Adults With Solid Tumors
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
Study of STP938 (Dencatistat) in Advanced Solid Tumours
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
BTM-3566 in Advanced Solid Tumors
Common conditions studied in San Antonio
- Advanced Solid Tumor (40 active studies)
- Advanced Solid Tumors (31 active studies)
- Obesity (30 active studies)
- Breast Cancer (26 active studies)
- Overweight (24 active studies)
- Ovarian Cancer (21 active studies)
Leading research sponsors in San Antonio
- The University of Texas Health Science Center at San Antonio
- Eli Lilly and Company
- AstraZeneca
- Pfizer
- Children's Oncology Group
Frequently asked questions
How many paid clinical trials are currently recruiting in San Antonio?
There are approximately 989 recruiting clinical trials in San Antonio, Texas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in San Antonio pay participants?
Most recruiting trials in San Antonio compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in San Antonio?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in San Antonio?
The most common conditions under active study in San Antonio include Advanced Solid Tumor (40), Advanced Solid Tumors (31), Obesity (30), Breast Cancer (26), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in San Antonio?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in San Antonio on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in San Antonio?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in San Antonio?
Recruiting research sites in San Antonio include University of Texas Health Science Center at San Antonio, NEXT Oncology, Children's Hospital of San Antonio, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in San Antonio right now?
The largest active categories in San Antonio are Cancer & tumors (293), Diabetes & metabolic (90), Neurology & pain (45). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of NEXT Oncology?
NEXT Oncology is located at 22151 BULVERDE RD STE 106, SAN ANTONIO, TX 78259-1850. Use the Google Maps link in the intro above to get directions.
How do I contact NEXT Oncology?
You can reach NEXT Oncology by phone at (281) 783-8162. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.